Myosotis Investments BV takes 48.4% stake in Kairos Biotech
Published
Myosotis Investments BV entered the register of Kairos Biotech Ltd, a transplant diagnostics firm, with a 48.4% stake across ordinary and preference shares.
Echiumbio Biotech Limited exited its 21.8% ordinary shareholding.
Echiumbio Holding BV exited its 18.6% preference shareholding.
The filing does not name recipients for either Echiumbio exit, while the overall register shows more shares than before, suggesting fresh funding, although some change may reflect a reorganisation. The filing was made on 14 September 2026 and covers changes spanning the multi-year period from 3 September 2024 to 3 September 2026.
Shareholder data
Source: Companies House confirmation statement (CS01) — period to , filed .
Changes in this confirmation statement
| Type | Shareholder | Shares | Change | Share classes |
|---|---|---|---|---|
| Exited | ECHIUMBIO BIOTECH LIMITED | 366,263 | — | ORDINARY 366,263 |
| Exited | ECHIUMBIO HOLDING BV | 313,030 | — | PREFERENCE 313,030 |
| New shareholder | MYOSOTIS INVESTMENTS BV | 939,962 | — | PREFERENCE 573,699 ORDINARY 366,263 |
Current shareholders (1)
| Shareholder | Total shares | Share classes |
|---|---|---|
| MYOSOTIS INVESTMENTS BV | 939,962 | ORDINARY 366,263 PREFERENCE 573,699 |
Similar companies
Companies with the most similar business descriptions.
- Quell Therapeutics LimitedCell & Gene Therapy · Immunology · Biotech
- Immunocore Holdings PlcBiotech · Pharma · Drug Discovery
- Barinthus Biotherapeutics (Uk) LimitedBiotech · Immunology · Drug Discovery
- Kymab LimitedBiotech · Drug Discovery · Cell & Gene Therapy
- Bastion Therapeutics LimitedCell & Gene Therapy · Biotech · Immunology
- Grey Wolf Therapeutics LimitedBiotech · Pharma · Drug Discovery
More rounds like this
Contact the editorial team at editorial@fundingspotter.com